MedWatch

Bavarian unconcerned by Moderna RSV advance: ”It's completely as expected"

Bavarian Nordic is not worried by the news that Moderna has announced a phase III trial of its RSV vaccine, positioning the US-based firm ahead of the Danish one in the race to reach the potentially lucrative RSV market. ”Old news,” says VP of Investor Relations & Communications Rolf Sass Sørensen.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Another competitor is now breathing down Bavarian Nordic’s neck, as Moderna announced its next step after a successful phase II with its vaccine against respiratory syncytial virus (RSV) on Tuesday.

Moderna is ready to enter phase III, which puts Bavarian Nordic even further back in the race to reach the potential billion-dollar RSV market. Other suitors, which happen to be ahead of Bavarian, include Johnson & Johnson, Glaxosmithkline and Pfizer. Despite the intensifying competition, the vice president of investor relations and communications at Bavarian Nordic, Rolf Sass Sørensen, isn’t quaking in his boots.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs